drug
afatinib dimaleate
Marketedupdated 3mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying afatinib dimaleate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 9, 2026
82 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (30)
- Jan 5, 2031patentUS 10004743*PED4.4y
- Jan 5, 2031patentUS 10004743*PED4.4y
- Jan 5, 2031patentUS 10004743*PED4.4y
- Jul 5, 2030formulationUS 100047433.9y
- Jul 5, 2030formulationUS 100047433.9y
- Jul 5, 2030formulationUS 100047433.9y
- Jun 19, 2030patentUS 8545884*PED3.8y
- Jun 19, 2030patentUS 8545884*PED3.8y
- Jun 19, 2030patentUS 8545884*PED3.8y
- Apr 10, 2030patentUS 8426586*PED3.6y
- Apr 10, 2030patentUS 8426586*PED3.6y
- Apr 10, 2030patentUS 8426586*PED3.6y
- Dec 19, 2029formulationUS 85458843.3y
- Dec 19, 2029formulationUS 85458843.3y
- Dec 19, 2029formulationUS 85458843.3y
- Oct 10, 2029compositionUS 84265863.1y
- Oct 10, 2029compositionUS 84265863.1y
- Oct 10, 2029compositionUS 84265863.1y
- May 9, 2027patentUS 9539258*PED263d
- May 9, 2027patentUS 9539258*PED263d
- May 9, 2027patentUS 9539258*PED263d
- Nov 9, 2026method-of-use (U-1950)US 953925882d
- Nov 9, 2026method-of-use (U-1950)US 953925882d
- Nov 9, 2026method-of-use (U-1950)US 953925882d
- Jul 13, 2026patentUS RE43431*PED
- Jul 13, 2026patentUS RE43431*PED
- Jul 13, 2026patentUS RE43431*PED
- Jan 13, 2026compositionUS RE43431
- Jan 13, 2026compositionUS RE43431
- Jan 13, 2026compositionUS RE43431
News(0)
no news has mentioned this drug yet
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that